Drug Trial Radar · NCT06141980
Study to Evaluate the Long Term Safety and Efficacy of DWP16001 in Patients With Type 2 Diabetes Mellitus
Last checked: Nov 19, 2026Latest source record: Nov 21, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
134
Planned (sponsor's estimate)
Start
Dec 2023
Primary completion
Sep 2025
Study completion Sep 2025
Sponsor
- Lead sponsor
- Daewoong Pharmaceutical Co. LTD.Industry
- Sponsor type
- Industry
- First posted
- Nov 21, 2023
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 19 years, up to 79 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The subjects, having voluntarily agreed to participate in the clinical trial and provided informed consent, will undergo screening tests. During Visit 1 (Screening), subjects meeting the inclusion/exclusion criteria will go through an 8-week stabilization period. At Visit 1-1, central laboratory tests will be conducted. If the test results meet the criteria for Visit 2 (Enrollment Visit), the subject will be eligible to participate in the clinical trial. The subjects will receive the investigational drug (DWP16001 0.3 mg) once a day for 52 weeks. They will visit the clinical trial site at weeks 8, 16, 24, 38, and 52 for safety and efficacy assessments during the 52-week treatment period.
Conditions
- T2DM (Type 2 Diabetes Mellitus)
Interventions
DWP16001 0.3 mgDrug
DWP16001 0.3mg, Tablets, Orally, Once daily
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety outcomes_Adverse events occurred during clinical trialsTime frame: from baseline up to 52 weeks
- Safety outcomes_ Change of blood pressureTime frame: from baseline to Week 8, 16, 24, 38, and 52 after administration of the IP
- Safety outcomes_ Change of heartbeatTime frame: from baseline to Week 8, 16, 24, 38, and 52 after administration of the IP
- Safety outcomes_ Change of body temperatureTime frame: from baseline to Week 8, 16, 24, 38, and 52 after administration of the IP
- Efficacy outcome_Change of HbA1cTime frame: from Baseline at Week 8, 16, 24, 38, and 52 after administration of the IP
- Efficacy outcome_Change of FPGTime frame: from baseline at Week 8, 16, 24, 38, and 52 after administration of the IP
- Efficacy outcome_Proportion of subjects achieving HbA1c target of < 6.5%Time frame: at Weeks 8, 16, 24, 38 and 52 after administration of the IP
- Efficacy outcome_Proportion of subjects achieving HbA1c target of < 7.0 %Time frame: at Weeks 8, 16, 24, 38 and 52 after administration of the IP
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.